---
title: "Bacil Pharma Ltd (524516) — Share Price, Financials & Analysis"
symbol: "524516"
company: "Bacil Pharma Ltd"
canonical: "https://tapetide.com/stocks/524516"
isin: "INE711D01018"
nse_symbol: "BACILPHARMALTD"
bse_code: "524516"
sector: "Healthcare"
industry: "Pharmaceuticals"
market_cap_cr: 27.82
generated_at: "2026-09-13T18:37:42.443Z"
---

# Bacil Pharma Ltd (524516)

Canonical page: https://tapetide.com/stocks/524516

## Company

- **NSE Symbol:** BACILPHARMALTD
- **BSE Code:** 524516
- **ISIN:** INE711D01018
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** bacilpharma.com

## About

Bacil Pharma Limited is a Mumbai-registered listed company incorporated in 1987. Although its stated business is pharmaceutical healthcare, it recorded no core operating revenue in FY26 and is currently an investment/other-income-led, non-operating company evaluating future business opportunities.[1] [2]

## Latest Price

## Key Fundamentals

Observed at 2026-09-11T04:41:06.608431Z.

- **Market Cap:** ₹27.82 Cr
- **Classification:** Microcap
- **P/E (reported):** 40.1
- **EPS (TTM):** ₹0.46
- **Book Value:** ₹17.55
- **Price to Book:** 1.05
- **Dividend Yield:** 0%
- **ROE:** 6.27%
- **ROCE:** 3.99%
- **Debt to Equity:** 0
- **Revenue (yearly):** ₹1.2 Cr
- **Net Income:** ₹1.6 Cr
- **EBITDA:** ₹1 Cr
- **52-Week High:** ₹61.8
- **52-Week Low:** ₹10.65
- **RSI (14):** 59.16

## Tapetide Score

- **Score:** 44 / 100
- **Score date:** 2026-09-04
- **Archetype:** Weak and Under Pressure
- **What it means:** Weak financials are the defining feature, and neither the valuation nor the trend reading is strong enough to offset them. Worth reading the risk flags and recent filings closely before anything else.
- **Pillar profile:** Quality: Weak · Valuation: Expensive · Momentum: Falling
- **Percentile:** 25 (of 4473 scored stocks)
- **Confidence:** 87%
- **Data coverage:** 90%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 72.5 | 9.89% |
| momentum | 3.49 | 13.19% |
| ownership | 50 | 26.37% |
| quality | 48.14 | 24.18% |
| valuation | 41.48 | 26.37% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Company has reduced debt.
- Company is almost debt free.
- Stock is trading at 1.12 times its book value

### Weaknesses

- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 3.18% over last 3 years.

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | 77.5% | 0.71% | 117.71% |
| ebitda margin growth | 0.1% | 29.87% | -283.58% | -101.2% |
| net income growth | -100% | 300% | 131% | 77% |
| revenue growth | 0% | 71.43% | 128.94% | 64.38% |
| roce | — | 149.38% | -182.1% | -64.76% |
| roe | — | 294.34% | 1% | -101.99% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Expenses | 0.04 | 0.05 | 0.06 | 0.04 | 0.07 | 0.06 | 0.07 | 0.11 | 0.03 | 0.02 | 0.07 | 0.02 |
| Operating Profit | -0.04 | -0.05 | -0.06 | -0.04 | -0.07 | -0.06 | -0.07 | -0.11 | -0.03 | -0.02 | -0.07 | -0.02 |
| Other Income | 0.03 | 0.03 | 0.02 | 0.01 | 0.56 | 0 | 0.09 | 1 | 0.05 | 0.06 | 0.11 | 0.09 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | -0.01 | -0.02 | -0.04 | -0.03 | 0.49 | -0.06 | 0.02 | 0.89 | 0.02 | 0.04 | 0.04 | 0.07 |
| Tax % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 24.72 | 0 | 0 | -1450 | 114.29 |
| Net Profit | -0.01 | -0.02 | -0.04 | -0.03 | 0.48 | -0.06 | 0.02 | 0.67 | 0.01 | 0.04 | 0.62 | -0.02 |
| EPS in Rs | -0.02 | -0.03 | -0.07 | -0.05 | 0.81 | -0.1 | 0.01 | 0.47 | 0.01 | 0.03 | 0.43 | -0.01 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Expenses | 0.29 | 0.26 | 0.18 | 0.16 | 0.16 | 0.17 | 0.19 | 0.25 | 0.25 | 0.14 |
| Operating Profit | -0.29 | -0.26 | -0.18 | -0.16 | -0.16 | -0.17 | -0.19 | -0.25 | -0.25 | -0.14 |
| Other Income | -3.42 | -0.07 | -0.12 | -0.07 | -3.7 | 0.07 | 0.13 | 0.66 | 1.24 | 0.31 |
| Interest | 0.03 | 0 | 0.01 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0.01 | 0.01 | 0.01 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | -3.75 | -0.34 | -0.32 | -0.23 | -3.86 | -0.1 | -0.06 | 0.41 | 0.99 | 0.17 |
| Tax % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -57.58 | — |
| Net Profit | -3.75 | -0.34 | -0.32 | -0.24 | -3.86 | -0.1 | -0.06 | 0.4 | 1.56 | 0.65 |
| EPS in Rs | -6.37 | -0.58 | -0.54 | -0.41 | -6.55 | -0.17 | -0.1 | 0.28 | 1.09 | 0.46 |
| Dividend Payout % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 6.53 | 6.53 | 6.53 | 6.53 | 6.53 | 6.53 | 6.53 | 6.53 | 13.97 | 13.97 |
| Reserves | -0.09 | -4.29 | -4.62 | -5.14 | -5.14 | -5.3 | -5.43 | -5.31 | 11.46 | 10.84 |
| Borrowings | 0.31 | 0 | 0.1 | 0.17 | 0.18 | 0.03 | 0.02 | 0.1 | 0.16 | 0 |
| Other Liabilities | 0.02 | 2.51 | 2.55 | 2.55 | 2.52 | 0.01 | 0.01 | 0.01 | 0.02 | 2.58 |
| Total Liabilities | 6.77 | 4.75 | 4.56 | 4.11 | 4.09 | 1.27 | 1.13 | 1.33 | 25.61 | 27.39 |
| Fixed Assets | 5.94 | 2.53 | 2.53 | 2.52 | 2.51 | 0.01 | 0.01 | 0.01 | 0 | 0 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0.54 | 1.15 | 0.96 | 0.43 | 0.37 | 0.31 | 0.43 | 0.61 | 21.36 | 24.24 |
| Other Assets | 0.29 | 1.07 | 1.07 | 1.16 | 1.21 | 0.95 | 0.69 | 0.71 | 4.25 | 3.15 |
| Total Assets | 6.77 | 4.75 | 4.56 | 4.11 | 4.09 | 1.27 | 1.13 | 1.33 | 25.61 | 27.39 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 0 | 1.44 | -0.3 | -0.38 | -0.4 | -4.01 | -0.15 | 0 | 0.4 | 0.71 |
| Cash from Investing Activity | 0.02 | -1.2 | 0.28 | 0.39 | 0.53 | 3.81 | -0.12 | 0.08 | 0.34 | -2.38 |
| Cash from Financing Activity | 0 | 0 | -0.16 | -0.06 | -0.07 | 0.33 | 0.06 | -0.06 | 2.08 | -0.62 |
| Net Cash Flow | 0.02 | 0.23 | -0.18 | -0.05 | 0.06 | 0.13 | -0.2 | 0.01 | 2.82 | -2.29 |
| Free Cash Flow | 0 | 1.14 | -0.3 | -0.38 | -0.4 | -4.01 | -0.15 | 0 | 0.4 | 0.71 |
| CFO/OP | 0 | -497 | 115 | 211 | 250 | 2506 | 88 | 0 | -160 | -284 |

### Ratios

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ROCE % | -1.49 | -6.01 | -8.47 | -2.8 | -5.75 | -7.07 | -12.61 | -13.11 | -0.97 | 3.93 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 42.67% | 42.67% | 42.67% | 42.67% | 20.7% | 10.6% | 0.2% | 0.2% | 0.08% | 0.08% | 0% | 0% |
| FIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| DIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 53.8% | 53.77% | 53.89% | 53.91% | 59.61% | 67.42% | 75.77% | 77.37% | 80.95% | 80.95% | 98.26% | 95.77% |
| Others | 3.53% | 3.56% | 3.44% | 3.42% | 19.69% | 21.98% | 24.03% | 22.43% | 18.97% | 18.97% | 1.74% | 4.23% |
| No. of Shareholders | 6647 | 6628 | 6770 | 6794 | 6902 | 7461 | 7638 | 7532 | 7431 | 7431 | 7226 | 7326 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Sell
- **Buy / Neutral / Sell:** 7 / 2 / 10

### Moving Averages — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 15.81 | Buy |
| EMA (10) | 16.38 | Buy |
| SMA (20) | 13.79 | Buy |
| EMA (20) | 16.04 | Buy |
| SMA (50) | 21.97 | Sell |
| EMA (50) | 21.87 | Sell |
| SMA (100) | 35.92 | Sell |
| EMA (100) | 29.88 | Sell |
| SMA (200) | 40.06 | Sell |
| EMA (200) | 36.17 | Sell |

### Oscillators — summary: **Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 62.33 | Neutral |
| MACD (12,26,9) | -0.75 | Buy |
| Stochastic (14,3,3) | 99.5 | Sell |
| ADX (14) | 44.79 | Buy |
| Williams %R (14) | 0 | Sell |
| ATR (14) | 1.04 | High Volatility |
| ROC (12) | 66.78 | Buy |
| Stoch RSI (14) | 100 | Sell |
| UO (7,14,28) | 88.27 | Sell |

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-08-31 | [Reg. 34 (1) Annual Report.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3a4b7c50-27dd-4652-b362-215c719ef963.pdf) |
| 2026-08-29 | [Board Meeting Outcome for Outcome Of Board Meeting Held On 29Th August 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=25a0d21a-dab0-45d6-a3fd-d92097eda8f0.pdf) |
| 2026-08-29 | [Intimation For Book Closure](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8ca86801-000b-406f-aa38-cb043f715f91.pdf) |
| 2026-08-29 | [Notice Of Annual General Meeting To Be Held On 23Rd September 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e03c97ff-2c32-4092-b920-5803295e7c72.pdf) |
| 2026-08-26 | [Board Meeting Intimation for Bacil Pharma Limited ("The Company") Will Be Held On 29Th August 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cbe4c773-1282-4c4f-b0eb-5db019155afe.pdf) |
| 2026-08-25 | [Board Meeting Outcome for Outcome Of Board Meeting Held On 25Th August 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=45264bd6-be73-4f4f-a9e2-0e202db4d2ef.pdf) |
| 2026-08-25 | [Appointment Of Director](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=702bff98-cbff-4116-a7c4-0d4ccf51b1a4.pdf) |
| 2026-08-17 | [Board Meeting Intimation for Intimation Of Board Meeting To Be Held On 25Th August 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=258893c7-7d12-4427-8e0a-2a366ecafc2c.pdf) |
| 2026-08-12 | [Board Meeting Outcome for Outcome Of Board Meeting Held On 12Th August 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5f4c9538-e00b-4a99-8f63-5c3ebf24ea8f.pdf) |
| 2026-08-06 | [Board Meeting Intimation for Intimation Of Board Meeting To Be Held On 12Th August 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ed55ea63-1fd4-4969-9ffe-fdada9f804f5.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-08-12 | [Un-Audited Financial Results For The Quarter Ended 30Th June 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b145dc47-9457-4a36-adac-2483e8603db2.pdf) |
| 2026-05-22 | [Audited Financial Results For 31St March 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fec535c4-fc4f-454b-b59d-a1b8205b5728.pdf) |
| 2026-02-13 | [Unaudited Financial Result For 31St December 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0a7403e5-7e35-414c-a366-675516346f85.pdf) |
| 2026-02-13 | [Revised Un-Audited Financial Result For 31St December 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=34a3b0bb-8ad3-447a-b282-b8e299c77686.pdf) |
| 2025-11-13 | [Un-Audited Financial Result For 30Th September 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=15f83abe-c3e6-4a32-8239-2bcfa9496357.pdf) |
| 2025-08-12 | [Results Financial Results For The Quarter Ended 30/06/2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=618a777a-71f2-4e8a-a1ac-279d404018a5.pdf) |
| 2025-05-26 | [Results-Financial Results For The Year Ended 31/03/2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bf46af0f-48e8-4db9-b828-a305be34741b.pdf) |
| 2025-05-26 | [Revised Audited Financial Result For The Quarter And Year Ended 31St March 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4b6e95a1-c449-423f-8b48-1ef229ceb582.pdf) |
| 2025-01-21 | [Outcome Of Board Meeting](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=85504263-4ca4-4059-8386-e42989f6afcc.pdf) |
| 2024-10-23 | [Outcome Of Board Meeting Held On 23Rd October 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ac30960e-64cb-4d7f-9316-f972d7f583ea.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 9 February 2026 - Received Rs.58,74,500 order from Indian Railways for 500A couplers and 150 sq.mm feeder cables; 2-year contract. | [Awarding of order(s)/contract(s) 9 February 2026 - Received Rs.58,74,500 order from Indian Railways for 500A couplers and 150 sq.mm feeder cables; 2-year contract.](https://nsearchives.nseindia.com/corporate/DHARA_09022026112414_Regulation_30_Tejas.pdf) |
| 5 Feb - Board meeting on 13 Feb 2026 to approve unaudited results for quarter ended 31 Dec 2025. | [Board Meeting Intimation for We Wish To Inform You That The Meeting Of The Board Of The Company Is Scheduled To Be Held On Friday, 13Th February, 2026 5 Feb - Board meeting on 13 Feb 2026 to approve unaudited results for quarter ended 31 Dec 2025.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/5e882fab-4e68-4395-b227-53078dce28e2.pdf) |
| 28 January 2026 - Received Rs.6.03 crore two-year AMC for train lighting coaches from Central Railway, Mumbai. | [Awarding of order(s)/contract(s) 28 January 2026 - Received Rs.6.03 crore two-year AMC for train lighting coaches from Central Railway, Mumbai.](https://nsearchives.nseindia.com/corporate/DHARA_28012026163614_Regulation_30_Given__By_Vishvanathan_S.pdf) |
| 27 Apr - Bacil Pharma reports it is not a large corporate under SEBI debt fundraising norms. | [Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 27 Apr - Bacil Pharma reports it is not a large corporate under SEBI debt fundraising norms.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/1786b1d6-375a-4860-922e-1e72b919ff89.pdf) |
| 27 Apr - Bacil Pharma confirms it is not a large corporate under SEBI debt fundraising framework. | [Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2 27 Apr - Bacil Pharma confirms it is not a large corporate under SEBI debt fundraising framework.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/f4366b13-e58e-4ca4-bdb0-7925e4829ef2.pdf) |
| 24 Feb - Company denies unpublished price-sensitive information; attributes price movement to market; confirms Reg 30 compliance (24 Feb 2026). | [Clarification On Price Movement 24 Feb - Company denies unpublished price-sensitive information; attributes price movement to market; confirms Reg 30 compliance (24 Feb 2026).](https://www.bseindia.com/xml-data/corpfiling/AttachHis/f797ec5b-e7be-400b-976b-64c67bfaf780.pdf) |
| 23 Feb - Norbexi acquired 2,075,000 shares (14.46%) of Bacil Pharma off-market on 19/02/2026. | [Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 23 Feb - Norbexi acquired 2,075,000 shares (14.46%) of Bacil Pharma off-market on 19/02/2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/6262250F_9F94_4317_813F_E9A35F0CB9E2_174046.pdf) |
| 2 March 2026 - Board on 2 Mar 2026 appointed secretarial auditor Murtuza Mandorwala and internal auditor H.B. Purohit for FY2025-26. | [Appointment 2 March 2026 - Board on 2 Mar 2026 appointed secretarial auditor Murtuza Mandorwala and internal auditor H.B. Purohit for FY2025-26.](https://nsearchives.nseindia.com/corporate/DHARA_02032026165120_Outcome_S.pdf) |
| 2 March 2026 - Board on 2 Mar 2026 appointed Murtuza Mandorwala (secretarial auditor) and H.B. Purohit & Co. (internal auditor) for FY2025-26. | [Change in Auditors 2 March 2026 - Board on 2 Mar 2026 appointed Murtuza Mandorwala (secretarial auditor) and H.B. Purohit & Co. (internal auditor) for FY2025-26.](https://nsearchives.nseindia.com/corporate/DHARA_02032026165640_Outcome_S.pdf) |
| 2 March 2026 - Board appointed secretarial auditor Murtuza Mandorwala & Associates and internal auditor H.B. Purohit & Co. for FY2025-26. | [Outcome of Board Meeting 2 March 2026 - Board appointed secretarial auditor Murtuza Mandorwala & Associates and internal auditor H.B. Purohit & Co. for FY2025-26.](https://nsearchives.nseindia.com/corporate/DHARA_02032026170358_Outcome_S.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/42daeb30-f9ef-4f57-a80d-58100fcbfeda.pdf) |
| from bse | [Annual Report 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/ce2fa8b5-74d7-4367-b34f-5d67329dc0fc.pdf) |
| from bse | [Annual Report 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/6bb67a7a-9e6c-4ac9-91cf-88c045479464.pdf) |
| from bse | [Annual Report 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/524516/76280524516.pdf) |
| from bse | [Annual Report 2021 from bse](https://www.bseindia.com/bseplus/AnnualReport/524516/70743524516.pdf) |
| from bse | [Annual Report 2020 from bse](https://www.bseindia.com/bseplus/AnnualReport/524516/66953524516.pdf) |
| from bse | [Annual Report 2019 from bse](https://www.bseindia.com/bseplus/AnnualReport/524516/5245160319.pdf) |
| from bse | [Annual Report 2018 from bse](https://www.bseindia.com/bseplus/AnnualReport/524516/5245160318.pdf) |
| from bse | [Annual Report 2017 from bse](https://www.bseindia.com/bseplus/AnnualReport/524516/5245160317.pdf) |
| from bse | [Annual Report 2016 from bse](https://www.bseindia.com/bseplus/AnnualReport/524516/5245160316.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:37:42.443Z.